INTRODUCTION
Allogeneic stem cell transplantation is an established treatment for malignant diseases such as leukemia, myelodysplasia, and myelofibrosis as well as non-malignant disorders such as severe aplastic anemia and congenital immune or enzyme deficiencies, with >40,000 transplants undertaken worldwide (Aljurf et al., 2014; Pineault and Abu-Khader, 2015) . Despite this success, $67% of patients who require allogeneic transplantation are not able to undergo this procedure due to the lack of matched donors (Oran and Shpall, 2012) . Umbilical cord blood (CB) banks have the potential to alleviate these obstacles due to broader representation of histocompatibility leukocyte antigen (HLA) types, less restriction on HLA matching, reduced incidence of graft versus host disease (GvHD), and rapid access compared to registries. However, widespread use of CB is impaired due to insufficient hematopoietic stem cell (HSC) numbers in single CB units, resulting in extended times to full engraftment (Ballen et al., 2013) . Transplants combining two unrelated CB units have attempted to overcome the shortfall in HSC number, although improvements are modest (Barker et al., 2001; Wagner et al., 2014) . Multiple efforts have been undertaken to attempt HSC expansion, but these have largely been empirical and rarely successful (Metcalf, 2008; Ogawa, 1993; Sauvageau et al., 2004) . Recently, promising HSC expansion protocols have employed small molecules such as prostaglandin E2, SR1, UM171, or UM729, although clinical efficacy remains elusive (Boitano et al., 2010; Fares et al., 2014; North et al., 2007) .
The unique self-renewal properties of HSCs are thought to be controlled by a combination of intrinsic and extrinsic signaling networks that finely balance the equilibrium among quiescence, proliferation, and differentiation. Generating increased numbers of HSC could come from controlling self-renewal or inducing self-renewal in the more numerous progenitor compartment. To achieve the latter, numerous signaling pathways would have to be appropriately fine-tuned. Small, non-coding RNAs such as microRNAs (miRNAs) act as post-transcriptional regulators of gene expression, and one miRNA can target hundreds of transcripts comprising an entire network of regulated genes, 
Enforced Expression of miR-125a Gives a Proliferative Advantage to HSCs
(A) RT-PCR expression levels of miR-125a in flow-sorted populations from the human Lin À CB hierarchy. Cells were sorted to high purity according to the scheme outlined in Figure S1A . RNU48 was used as an endogenous control, and miR-125a levels were normalized to RNU48 levels. (E) Frequency of CMP, GMP, and MEP populations recovered from total BM within the CD34 + CD38 + committed progenitor compartment.
(F) Proportion of HSC, MPP, and MLP from total BM within the CD34 + CD38 À primitive compartment 12 and 24 weeks post-transplant.
(legend continued on next page) positioning miRNAs as pivotal regulators of cellular homeostasis (Bartel, 2009; Filipowicz et al., 2008) . miRNA profiling of hematopoietic stem and progenitor cells (HSPCs) has identified several miRNAs as differentially expressed and functionally able to govern HSC properties (Gerrits et al., 2012; Lechman et al., 2012; O'Connell et al., 2008 O'Connell et al., , 2010 . The family of miR-125 is particularly interesting, as they are highly expressed in murine HSCs (Gerrits et al., 2012; Guo and Scadden, 2010; O'Connell et al., 2010) . This family consists of three paralogs (miR-125a, miR-125b1, and miR-125b2) sharing an identical seed sequence and exerting similar effects on HSPCs (Wojtowicz et al., 2014) . MicroRNA-125a expression levels significantly decrease upon hematopoietic differentiation in mice (Gerrits et al., 2012; O'Connell et al., 2010) , implying a correlation between the level of miR-125 activity and differentiation status. Ectopic expression of miR-125 (a, b1, or b2) in murine bone marrow (BM) cells results in an increased self-renewal, a proliferative advantage to HSCs and the initiation of myeloproliferation or leukemia, depending on miR-125 expression level (O'Connell et al., 2010; Wojtowicz et al., 2014) . Targeted downregulation of miR-125a and miR125b caused reduced HSPC self-renewal in vitro (Guo and Scadden, 2010) and reduced proliferation and blood cell output in vivo (Ooi et al., 2010; Wojtowicz et al., 2014) , confirming a pivotal role for miR-125 family members in the molecular control of HSC self-renewal.
In the current study, we explored the potential of a single miRNA, miR-125a, to confer long-term repopulating ability to non-stem cell populations. Here, we report that enforced expression of miR-125a endows multipotent progenitors (MPPs) with enhanced self-renewal potential, offering an innovative means to use MPPs to augment limited sources of HSCs to improve clinical outcomes.
RESULTS
Enforced Expression of miR-125a Increases Human HSC Self-Renewal Since miR-125a is highly expressed within mouse long-term HSCs (LT-HSCs) and has been shown to increase their selfrenewal activity (Gerrits et al., 2012; Guo and Scadden, 2010; O'Connell et al., 2010; Ooi et al., 2010; Wojtowicz et al., 2014) , we wanted to evaluate if these attributes are evolutionarily conserved within human hematopoiesis. We sorted immunophenotypically defined HSC and progenitor cell subsets from human-lineage-depleted CB ( Figure S1A ) (Doulatov et al., 2010; Notta et al., 2011) to obtain a detailed expression profile of mature miR-125a. We observed that the highest expression levels of miR-125a were restricted to the HSC-enriched CD34 Figure 1A ). These data demonstrate an inverse correlation between differentiation state and miR125a expression levels.
To study the function of miR-125a in human HSPCs, we generated a lentiviral vector with miR-125a (miR-125OE) under a constitutive SFFV promoter using an orange fluorescent protein (OFP) reporter ( Figure 1B) . To determine the impact of increased miR-125a expression ( Figure S1B ) on human HSPC function, CD34 + CD38 À human CB HSPCs transduced with miR-125OE
and control vector transduced cells were analyzed in xenotransplantation assays ( Figure 1B) . At 12 and 24 weeks after transplantation, we observed significant increases in human chimerism within distant BM sites in the miR-125aOE group compared to controls; chimerism levels in the injected femur (IF) were significantly increased only at 12 weeks ( Figure 1C ). Mice transplanted with miR-125OE cells also exhibited white BM and splenomegaly ( Figure S1C ). Furthermore, within enlarged spleens, we found increased proportions of CD19 + CD10 + CD20 À B lymphoid cells, suggesting a partial B cell differentiation block at the pro-B cell stage ( Figure S1D ). Examination of the lineage distribution of OFP + cells in the BM revealed that all lineages were present, with significant expansion of the CD41 + megakaryocyte population ( Figure 1D ) and an increased CD3 + T cell population. At the progenitor level ( Figures 1E and S1E ), we observed a trend for increased GMPs and decreased MEP frequency in the BM, whereas the frequency of the multilymphoid progenitor fraction (MLP) was significantly increased at the expense of immunophenotypic HSCs and MPPs in the primitive compartment ( Figures 1F and S1E ). These observations are in line with previous reports in murine HSPCs pointing to conservation of function across species (Gerrits et al., 2012; Guo and Scadden, 2010; O'Connell et al., 2010) . The self-renewal potential of transduced human HSC within primary engrafted mice was assessed using quantitative secondary transplantation assays. Recipients transplanted with miR-125OE cells showed higher chimerism levels compared to controls, and the HSC frequency increased by 4.4-and 5-fold in miR-125OE recipients in independent experiments (Figures 1G and S1F), similar to published murine studies (Gerrits et al., 2012; Guo and Scadden, 2010; O'Connell et al., 2010) . Figure 2G ), and in no case did we observe myeloproliferative disease or leukemia in mice engrafted with miR-125OE human CB cells. Finally, to evaluate the long-term self-renewal potential of miR-125a expressing MPP, we transplanted the secondary MPP grafts into tertiary recipients for another 10 weeks. After a total of 30 weeks in mice, we observed small but measurable multi-lineage grafts both from CD34 + CD38 À CB progenitors and MPP-expressing miR125a ( Figures S2A-S2D ). To distinguish between rare contaminating HSCs or enhanced self-renewal of MPPs as the primary mechanism for the observed MPP phenotype in secondary and tertiary mice, we used a modified splinkerette PCR approach to assess the clonality of secondary miR-125OE MPP grafts. Our data demonstrate that miR-125OE MPP BM grafts were oligoclonal, with no lentivirus insertions near or within strong oncogenes (Table  S1 ), suggesting that the enhanced self-renewal observed in miR-125OE MPP mice was not attributable to rare contaminating HSCs. Given that our data strongly suggests that MPPs are frequently endowed with enhanced self-renewal potential, we should be able to model this phenomenon at the clonal level. Using in vitro long-term culture initiating cell (LTC-IC) assays that were established with presorted transduced MPP (Table S2) , we found that miR-125OE increased the LTC-IC frequency of transduced MPPs by $4-fold compared to controls (1/11.9 versus 1/44.7, respectively, p = 0.0000000975), with a concomitant $9-fold increase in colonies/LTC-IC (6.6 ± 2.1 versus 54.4 ± 11.6, p = 0.0041). Together, these data strongly suggest that the enhancement of self-renewal by enforced expression of miR-125 occurs not only in HSCs but also in MPPs and in an asyet-unidentified population within the CD34 + 38 + committed progenitor compartment.
miR-125a Expression Prolongs Self-Renewal Activity in Murine MPPs
To assess whether this enhanced self-renewal induced by miR125a is conserved in mice, we overexpressed miR-125a (Figure 3A) in Lin Figure S3A ). We confirmed enforced overexpression by qPCR ( Figure S3B ) and performed a series of in vivo HSC assays. As controls, we included cells transduced with a vector expressing only GFP and a vector expressing a mutant form of miR-125a, where the fourth base of the seed sequence was modified (for a seed 5 0 -CCCTGAC-3 0 miR-125 mut4T/C ) ( Figure 3A ). The mutant construct was as effectively expressed and processed as non-mutated miR125a ( Figure S3B ). We competitively transplanted transduced cells in limiting dilution to lethally irradiated recipients together with a high dose of 2 3 10 6 fresh BM cells ( Figure 3A ) and monitored GFP + chimerism over time. As expected, miR-125OE in LT-HSCs strongly increased their competitive reconstitution activity compared to controls, similar to what we and others have reported ( Figure 3B ) (Gerrits et al., 2012; Guo and Scadden, 2010; O'Connell et al., 2010; Ooi et al., 2010; Wojtowicz et al., 2014) and similar to our results using human cells. Control transduced progenitors (and the mutant construct; data not shown) were unable to provide long-term repopulation ( Figure 3C ). By contrast, miR-125OE progenitors generated robust, high levels of multi-lineage reconstitution up to 16 weeks post-transplantation ( Figure 3C ). Limiting dilution experiments demonstrated a 10-fold expansion of stem cell pool size ( Figures 3D, 3E , and S4A). Importantly, miR-125OE progenitors sustained long-term blood cell production with an estimated frequency similar to control LT-HSCs ( Figures 3D, 3E , and S4A). Using cellular barcoding (for gene transfer efficiency and cell doses, see Figure S4B ), we observed a significant increase in the number of clones contributing to myeloid engraftment upon miR-125a overexpression, indicating that induction of stem cell activity in progenitors was not a rare event, and likely not from contamination of rare LT-HSC ( Figure 3F ). At week 20 post-transplantation, we observed a reduced number of clones compared to week 4, but overall, the numbers of contributing clones were comparable in all groups ( Figure 3F ). Similar to our human CB data, mouse 125OE progenitors were able to sustain multi-lineage potential with myeloid skewing represented by increased numbers of Gr-1 + cells ( Figure 3G ) and increased numbers of GMPs, at the expense of MEPs ( Figure 3H ). To assess the potential of miR-125a to induce self-renewal, we serially transplanted 10 7 BM cells from primary recipients into lethally irradiated secondary recipients. While the repopulating potential of control LT-HSCs in secondary recipients was restricted to short-term engraftment (up to 6 weeks, most probably due to the high dose of competitors used in the first round of transplantation), the secondary recipients transplanted with miR-125OE LT-HSCs or progenitors were highly reconstituted, with an increased frequency of myeloid cells 20 weeks posttransplantation in peripheral blood (Figures 4C and 4D) . No lethality was observed in primary recipients. However, in secondary mice, we observed $20% mortality, starting at week 32, in mice transplanted with either miR-125OE LT-HSC or progenitors. Necropsy revealed increased white blood cell (WBC) counts, splenomegaly, pale bones, and blast-like cells in the blood. Fluorescence-activated cell sorting (FACS) analysis of BM and spleen revealed dominance of EGFP + cells of myeloid origin (Gr-1 + and/or Mac-1 + , a MPN-like phenotype, as previously described; Gerrits et al., 2012 ; data not shown). In tertiary recipients, mortality further increased to 40% for 125OE progenitors, and 60% for 125OE LT-HSCs. Surviving mice in the tertiary transplantation showed no engraftment ( Figure 4E ). In addition, mice transplanted with 125OE progenitors exhibited an increased fraction of erythroid progenitors ( Figures S5A  and S5B ). These data suggest that both LT-HSCs and progenitors overexpressing miR-125a remained functionally active for significantly longer periods of time compared to control cells ( Figure 4F ), and the cell type distribution of GFP + cells in secondary recipients 20 weeks post-transplantation showed myeloid skewing in mice transplanted with LT-HSC overexpressing miR-125a. We postulated that the myeloproliferative disease observed within 125OE mice could be due to a combination of miR-125-induced intrinsic changes and replicative stress ( Figure 4E ). To explore the role of replicative stress, we transplanted control and miR-125OE LT-HSCs into non-irradiated W41 recipients ( Figure 4G ). During the 11-month follow-up period, chimerism levels in 125OE LT-HSCs increased from 26% at transplantation reaching upward of 90% after 9 weeks post transplantation and remained very high. In contrast, the contribution of control LT-HSCs was stable over time, starting at 30% and slightly decreasing to 20% at week 45 ( Figure 4H ). In this non-irradiated model, we observed only $40% mortality in mice transplanted with miR-125OE HSC, a 50% reduction compared to serial transplantation, where replicative stress is augmented ( Figure 4I ). These data suggest that replicative stress, due to irradiation and accompanying cytokine storm, contributes to the development of myeloproliferative disease in 125OE murine cells.
As recently reported, miR-125a overexpression leads to changes in expression of several HSC markers, including Sca-1, c-Kit, and CD150, precluding standard LT-HSC isolation from repopulated mice (O'Connell et al., 2010; Wojtowicz et al., 2014) . To determine which cell population contained secondary repopulating potential, we harvested BM cells from reconstituted primary recipients and sub-fractionated GFP 
SILAC Reveals a miR-125a-Specific Network of Targets
To gain more insight in the molecular network of miR-125a targets, we performed stable isotope labeling by amino acids in cell culture (SILAC) proteomics in the 32D murine hematopoietic progenitor cell line (Ong et al., 2002; Ward et al., 1999) . To do this, we expressed either miR-125a, miR-125 mut4T/C or a control vector and cultured cells in media with isotope-labeled amino acids ( Figure 5A ). We detected a total of 4,789 expressed proteins in duplicate experiments when analyzing fold-change expression ratios, comparing cells expressing the control vector with those expressing miR-125a and control vector with 125 mut4T/C samples. As the induction of a longterm repopulating program in HSPCs was largely seed sequence dependent, we excluded proteins that were similarly affected by both miR-125a and 125 mut4T/C . This filtered out previously reported miR-125 targets such as Bak 1, Traf 6, Klf13, and Bmf (Guo and Scadden, 2010; O'Connell et al., 2010; Ooi et al., 2010 ) ( Figure 5B ). We identified 217 proteins that were differentially expressed upon miR-125a overexpression. Of these, 11 genes contained a 3 0 UTR target sequence that is perfectly complementary to the seed sequence of miR-125 ( Figure 5C ); ten targets showed decreased protein levels upon miR-125a overexpression in our cell system and were therefore considered to be direct miR-125 targets. These targets include p38 kinase, a negative HSC self-renewal regulator (Ito et al., 2006) , and its inhibition leads to ex vivo HSC expansion (Wang et al., 2011) , three protein tyrosine phosphatases (Ptpn1, Ptpn7, and Smek1, all known to suppress cytokine signaling and negatively regulate MAP kinases), a ubiquitin ligase (Syvn1, shown to block differentiation of embryonic stem cells; Yagishita et al., 2005) , and Vps4b and M6pr, which are involved in transport of protein to vesicles and their lysosomal degradation. In addition, we identified interleukin-16 (IL-16) and Txnrd1, the latter gene playing a role in protection against oxidative stress (Peng et al., 2014) .
To gain further insight into the mechanism whereby miR-125a was exerting its biological effects on human HSPCs, we performed label-free protein mass spectrometry on 100,000 sorted mO + CD34 + human cord blood (huCB) HSPCs transduced with miR-125a or control vector. We were able to reliably quantify 6,687 protein groups ( Figure S5D ), and 517 of them showed a significant change (p < 0.05) between 125OE and control samples (Table S3) . Gene set enrichment analysis (GSEA) of the proteomics dataset identified pathways and leading edge genes directly targeted by miR-125a. In post-analysis, predicted Data in (E)-(H) reflect mean values ± SD. Statistical significance was assessed using a non-parametric Mann-Whitney test, where *p < 0.05, **p < 0.01, and ***p < 0.001. miR-125a targets were correlated with proteomic-modulated pathways ( Figure 5D ). The most significant pathways centered on JUN kinase activation, FAS signaling, stress-activated kinase signaling, Toll-like receptor signaling, interferon gamma signaling, and the NoRC complex, an epigenetic pathway involved in heterochromatin formation ( Figures 5D and 5E ). These data suggest that miR-125 exerts its effects on HSPCs by downregulating several genes within multiple pathways. Our data also confirm that P38 MAPK14 and PTPN1 are miR-125a targets in both murine and human HSPCs.
To validate identified targets, we performed nanofluidic proteomic analysis and confirmed the suppression of p38, Ptpn1 and Ptpn7, and Vps4b in cell lines used for SILAC ( Figure S6A ). To assess the downregulation of miR-125a targets in human CD34 + and mouse LT-HSCs and progenitors overexpressing miR-125a, we measured the expression of p38, Ptpn1, and Ptpn7, as well as Smek1 transcripts, by qPCR. We confirmed that all tested targets showed decreased expression compared to controls in both mouse and human cells ( Figures 6A, 6B , and 6E). We were also able to verify the repression of these targets at the protein level by western blot or immunofluorescence in transduced human CD34 + CB cells or sorted and transduced mouse LT-HSCs and progenitors ( Figures 6C, 6D , and 6F). Together, these data suggest that the endowment of an HSC-like selfrenewal program in hematopoietic progenitors that normally lack self-renewal capacity upon miR-125a overexpression is linked to repression of genes controlling the p38/mitogen-activated protein kinase (MAPK) pathway as well as several other pathways. Furthermore, our results reinforce the notion that miR-125a exerts similar functions in mouse and human cells.
DISCUSSION
Our study provides key insights into the powerful role that miRNAs can play in the regulation of HSC expansion/self-renewal properties. Previous work demonstrated expansion of the HSC pool upon miR-125 expression (Ooi et al., 2010) . Here, we establish that miR-125a can endow repopulation potential to progenitor populations and potently increase their self-renewal capacity. Our findings highlight the possibility of generating MPPs with enhanced self-renewal to augment limited sources of HLA-matched CB-derived HSCs to improve transplant outcomes. As CB-transplant-related mortality is influenced by low numbers of infused HSCs, rapid in vitro expansion of CB progenitors could increase the transplanted dose of stem cells, thus accelerating engraftment and reducing complications. Although it may be possible to therapeutically employ miR-125a to confer MPPs with self-renewal capacity, it is more likely that smallmolecule regulation of several critical miR-125a targets will be required to fully translate our work. In the future, combinatorial approaches combining miR-125a modified MPPs with existing small-molecule compounds like PGE2, SR1, and UM171 (Boitano et al., 2010; Fares et al., 2014; North et al., 2007) may support expansion of undersized HLA-matched CB units, allowing them to become a selected source of cells for transplantation. The development of myeloproliferative disease/leukemia upon miR-125a overexpression in murine cells in secondary and tertiary recipients is in agreement with previous reports (Bousquet et al., 2010; Gerrits et al., 2012; O'Connell et al., 2010) and has been shown to be dependent upon sustained expression of miR-125a (Guo et al., 2012) and dosage (O'Connell et al., 2008 (O'Connell et al., , 2010 . Our data suggest the miR-125a-induced myeloproliferative disease occurs, in part, as a function of replicative stress. We surmise that with careful titration of miR-125 levels, it may be possible to exploit the beneficial self-renewal effects of miR-125 without incurring the malignant side effects. Interestingly, overt malignancy was never observed in human xenografts through three serial transplantations (30 weeks total), suggesting that the inherent susceptibility of murine cells to oncogenic transformation may contribute to the development of (pre-) malignancy (Balmain and Harris, 2000; Rangarajan et al., 2004) . We cannot completely discount the possibility that vector integration contributed to malignant transformation. However, we deem this unlikely, considering the reproducibility of the acquired phenotypes and the absence of any known strong oncogenes in insertion site analysis. In addition, our data on cellular barcoding confirm that mice transplanted with LT-HSCs or progenitors overexpressing miR-125a had polyclonal repopulation similar to control LT-HSC, excluding the possibility that engraftment results from clonal dominance of a single clone.
We found similar behavior between control HSCs and miR125a-transduced MPPs regarding their long-term multi-lineage (K) The survival curve of non-irradiated W41 recipients transplanted with control or miR-125a-overexpressing LT-HSCs. All data reflect mean values ± SD, except for (K), which shows mean values ± SEM. Statistical significance was assessed using a non-parametric Mann-Whitney test, where *p < 0.05, **p < 0.01, and ***p < 0.001.
repopulating ability, self-renewal potential, and lineage distribution in transplanted recipients, both in mouse and human systems. This similarity points to a common mechanism whereby miR-125a functions to govern stem cell properties. Using proteomic analysis, we uncovered a subset of the relevant miR-125a-targeted pathways. Our study predicts that several of our identified targets should normally act to repress self-renewal in cells downstream of HSCs. Of the ten identified targets in murine cells, four are involved in the MAPK signaling pathway. The best-known and most-studied candidate protein is p38. Chemical inhibitors of p38 activity have previously shown efficacy in ex vivo mouse and human HSC expansion protocols (Baudet et al., 2012; Wang et al., 2011) . Another candidate target is PTPN1, of which little is known in the hematopoietic system. Loss of PTPN1 leads to increased numbers of pro-and pre-B cells in the BM (Dubé et al., 2005) , similar to previous reports showing increased numbers of pro-B cells upon miR-125b overexpression (Chaudhuri et al., 2012) and correlating with our human CB xenotransplantation data. Moreover, deletion of PTPN1 in fibroblasts leads to suppression of Erk signaling (Dubé et al., 2004) and increased insulin growth factor-1 (IGF-1)-induced AKT protein kinase B activity (AKT/PKB) (Buckley et al., 2002) . Constitutive activation of AKT in HSPCs has been shown to deplete B lymphocytes and induce myeloid skewing and the development of myelo- All data reflect mean values ± SEM. Statistical significance was assessed using a non-parametric Mann-Whitney test, where *p < 0.05, **p < 0.01, and ***p < 0.001.
proliferative disorders that progressed to leukemia (Helgason et al., 1998; Zhang et al., 2006) . We speculate that PTPN1 downregulation may similarly activate AKT in HSPCs, resulting in myeloid skewing and a block in B cell differentiation. However, the exact direct and indirect contribution of each individual miR-125a target in moderating self-renewal activity within progenitors requires additional studies. Multiple targets within several pathways are probably required to fully recapitulate the effects of miR125a on MPPs.
Irrespective of the precise mechanism of action, our findings provide clear evidence that miR-125a confers hematopoietic stem cell potential to cells that are normally devoid of this activity. Our results open the prospect of searching for other regulators that have this capability laying the foundation for utilizing progenitors in clinically relevant therapeutics. Molecular identification and functional evaluation of the full complement of miR-125a targets may allow the dissection of targets inhibiting self-renewal and distinguishing them from targets that may be closely aligned with malignancy. Furthermore, small-molecule screening and candidate identification on hematopoietic progenitor populations using induction of miR-125a as an operational readout could circumvent the requirement for virally enforced miRNA expression and accelerate the clinical application of miR-125a for CB transplantation. 
Lentiviral and Retroviral Constructs and Transduction
For the human part of the study, the lentiviral vector for ectopic miRNA expression (gain of function) has been described previously (Gentner et al., 2010) .
In the murine part of the study, we used a retroviral vector, miR-125a, and mut 4T/C cells were cloned as previously described (Gerrits et al., 2012; Wojtowicz et al., 2014) .
NSG Repopulation Assay
Male NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; Jackson Laboratory) were sublethally irradiated (225 cGy) 24 hr before intrafemoral injection.
Competitive transplantation was performed using the equivalent of 400 HSCs, 400 MPPs, and 1,000 MLP cells after overnight culture in low-cytokine conditions. Limiting dilution analysis of human CD34 + /CD38 À CB cell was performed a secondary mouse was scored as positive if it had >0.5% hCD45 + , mOrange + BM engraftment 8 weeks post transplantation. HSC frequency was estimated using ELDA software (http://bioinf.wehi.edu.au/software/ elda/; Hu and Smyth, 2009 ). C57BL/6 (B6) mice were purchased from Harlan Laboratories. C57BL/6.SJL mice were bred at the Central Animal Facility of University Medical Centre of Groningen (Groningen, the Netherlands). All animal experiments were approved by the University of Groningen Animal Care Committee.
Lentiviral Insertion Site Analysis by Modified Splinkerette PCR
To determine the lentiviral integration sites we used a splinkerette PCR approach (Uren et al., 2009 ) that we modified to be non-restrictive and have increased sensitivity for low DNA input amounts (see Supplemental Experimental Procedures). For identified integration sites in MPP-engrafted mice, see Table S1 .
Cellular Barcoding
Cells were isolated and transduced as described above (see also Verovskaya et al., 2013 
Hematopoietic Cell Transplantation and Blood Analysis
For limiting dilution experiments, cells were injected in given doses (Figure S3A) into lethally irradiated (9 Gy) female B6 recipients together with 2 3 10 6 fresh BM B6 cells. Blood samples were taken every 4-6 weeks and stained with antibodies against CD45.1 and CD45.2 to determine the donor chimerism and CD3ε, Gr-1, and B220 for FACS analysis. HSC frequency was estimated using ELDA software (http://bioinf.wehi.edu.au/ software/elda/).
Serial BM Transplantation
Primary recipients were sacrificed at 16 weeks post-transplantation for BM collection prior to secondary transplantation. 10 7 whole BM cells were transplanted into lethally irradiated secondary recipients. For tertiary recipients, donors were sacrificed 24 weeks post-secondary transplantation, and 5 3 10 6 whole BM cells were injected together with 5 3 10 5 fresh competitor cells from B6.
qPCR RNA was extracted from 25,000 to 30,000 GFP + cells using the miRNeasy Kit (QIAGEN), and commercially available TaqMan probes for miRNA qPCR or primers (Table S4) were used according to the manufacturer's protocol.
Label-free Quantitative Proteomics Analysis
The raw files were analyzed using MaxQuant version 1.5.2.8 (Cox and Mann, 2008 ) and standard settings. For differentially expressed proteins, see Table S3 . For sample preparation details, see Supplemental Experimental Procedures.
Quantitative Mass Spectrometry: SILAC The murine 32D cell line was used for to identify miR-125a targets. After transduction, GFP + cells were FACS sorted and expanded prior to stable isotope labeling as previously reported (Meenhuis et al., 2011) . A nano-high performance liquid chromatography (HPLC) system consisting of Easy-nLC 1000 and Q-Exactive (Thermo Fisher Scientific) was used.
Statistical Analysis
Unless otherwise stated, mean ± SEM values are shown in the graphs. For pairwise comparison, a Mann-Whitney U test was applied. Statistical analysis was performed using PRISM 6 (GraphPad Software). For proteomics data analysis, Student's t test with Bonferroni correction was applied.
Western Blot Analysis
For immunoblotting, proteins were transferred to PVDF membranes, incubated with the specific antibody (anti-p38, Cell Signaling #9212 1:1,000; anti-PTPN1, LifeSpan BioSciences #LS-C61924 1:500; and mouse anti-GAPDH, 1:10,000, Sigma) followed by peroxidase-conjugated secondary antibodies. Bands were visualized on Amersham Hyperfilm (GE Healthcare).
Nanofluidic Proteomic Analysis
The expression levels of p38 in transduced GFP + 32D cells used for SILAC or in LT-HSCs and progenitors overexpressing miR-125a were investigated by a size-based Simple western immunoassay, using a WES device (Protein Simple).
Immunofluorescence
To measure protein expression levels in transduced GFP+ LT-HSC or progenitors (Lin-Sca-1+c-Kit+ depleted from CD150 + 48-cells), cells were stained with antibodies directed against p38 (1:50, Cell Signaling, #9212) and Ptpn1 (1:100, Millipore, clone# ABS40). We used rabbit-specific IgG conjugated with Alexa-633 (Molecular Probes, Invitrogen) as a secondary antibody. For nuclear staining we treated cells with DAPI (Sigma). 
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